Journal
Blood Advances
Publication Date
12-9-2025
Volume
9
Issue
23
First Page
6205
Last Page
6217
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2024015600
Rights and Permissions
Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor Á, Townsend W, André M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C. Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study. Blood Adv. 2025 Dec 9;9(23):6205-6217. doi: 10.1182/bloodadvances.2024015600. © 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Herrera, Alex F; Bartlett, Nancy L; and et al., "Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: A phase 2 study." Blood Advances. 9, 23. 6205 - 6217. (2025).
https://digitalcommons.wustl.edu/oa_4/5939
Additional Links
Supplemental material is available for this article at publisher site.
